Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Summary

This phase II trial is studying how well giving combination chemotherapy works in treating young patients with recurrent or resistant malignant germ cell tumors. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Conditions

• Childhood Extracranial Germ Cell Tumor
• Childhood Extragonadal Malignant Germ Cell Tumor
• Childhood Malignant Ovarian Germ Cell Tumor
• Childhood Malignant Testicular Germ Cell Tumor
• Ovarian Choriocarcinoma
• Ovarian Embryonal Carcinoma
• Ovarian Yolk Sac Tumor
• Recurrent Childhood Malignant Germ Cell Tumor
• Recurrent Malignant Testicular Germ Cell Tumor
• Recurrent Ovarian Germ Cell Tumor
• Testicular Choriocarcinoma
• Testicular Embryonal Carcinoma
• Testicular Mixed Choriocarcinoma and Embryonal Carcinoma
• Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
• Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor
• Testicular Yolk Sac Tumor

Interventions

DRUG

Carboplatin

Given IV

BIOLOGICAL

Filgrastim

Given IV or subcutaneously

DRUG

Ifosfamide

Given IV

OTHER

Laboratory Biomarker Analysis

Optional correlative studies

DRUG

Paclitaxel

Given IV

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• Children's Oncology Group

  lead NETWORK

Principal Investigators

• Carlos Rodriguez-Galindo · Children's Oncology Group

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Max Age

21 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2007-11-05

Primary Completion

2012-03-01

Completion

2018-06-30

Countries

• United States
• Australia
• Canada
• Puerto Rico

Study Locations